Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Seeing optic neuritis through myopic eyes.
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon Beta-1a in patients with multiple sclerosis.
Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study.
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.
In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells.
Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury.
IFN-γ Signaling to Astrocytes Protects from Autoimmune Mediated Neurological Disability.
Recommendations for diagnosis and management of multiple sclerosis.
Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter.
Alteration of CD1 expression in multiple sclerosis.
What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
Naltrexone
Inhibition of autoimmune encephalomyelitis by a tetracycline.
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.
Oral Agent Outcomes
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
The microglial sensome revealed by direct RNA sequencing.
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
Multiple Sclerosis: Changes in Microarchitecture of White Matter Tracts after Training with a Video Game Balance Board.
Biochemical Markers of Autoimmune Diseases of the Nervous System.
Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: A meta-analysis of 6977 subjects.
Platelets provide a bounty of potential targets for therapy in multiple sclerosis.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR
No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis.

Pages